BioNTech SE (BNTX) on Wednesday announced the approval of matters relating to the exchange offer for all outstanding shares of CureVac N.V. (CVAC) at the extraordinary general meeting held by CureVac on November 25.
At the EGM, over 99.16% of votes cast by CureVac shareholders were in favor of the proposals relating to the offer.
BioNTech expects to complete the pending offer as soon as reasonably practicable.
BioNTech (BNTX) agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly $1.25B in June.
Offer set to expire at 9:00 am Eastern Time on December 3, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, due to operational deadlines.
